Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

Vertex, Inc. (NASDAQ:VERX), is not the largest company out there, but it led the NASDAQGM gainers with a relatively large price hike in the past couple of weeks. While good news for shareholders, the ...

Metafin will use the newly raised funds to deepen its presence in core markets, expand into new states, and strengthen its ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...

Today, CRISPR Therapeutics has only reached that approval finish line once, while Vertex has passed it multiple times. However, if CRISPR Therapeutics continues to deliver positive clinical trial ...

Meanwhile, for fiscal 2025, analysts expect Vertex Pharmaceuticals to report an ... Meanwhile, the company's bottom-line also exceeded the consensus estimates by a notable margin.